Related Experiment Video
Updated: Feb 12, 2026

Synthesis, Cellular Delivery and In vivo Application of Dendrimer-based pH Sensors
Published on: September 10, 2013
PEGylated Heterofunctional Dendrimers Enable Multivalent Diclofenac Delivery for ROS-Driven Anticancer Activity
Arunika Singh1, Natalia Sanz Del Olmo1,2,3, Michael Malkoch1
1Department of Fibre and Polymer Technology, KTH Royal Institute of Technology, Stockholm 100 44, Sweden.
None:
Cancer drug development faces escalating costs and limited success, driving interest toward drug repurposing strategies. Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID) with emerging anticancer potential, exhibits poor aqueous solubility and rapid systemic clearance, limiting its chemotherapeutic suitability. Here, we engineered PEGylated heterofunctional polyester dendrimers (HFDs) as modular nanocarriers that enable controlled multivalent presentation of diclofenac through orthogonal chemistry. Diclofenac was conjugated within the dendritic interior using copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) while peripheral PEGylation was introduced through anhydride esterification. First- and second-generation constructs, G1-(Dicl)3-(mPEG)6 and G2-(Dicl)9-(mPEG)12, assembled into amphiphilic core-shell nanostructures with hydrodynamic diameters of 170-330 nm and well-defined drug loading. G1-(Dicl)3-(mPEG)6 demonstrated the strongest therapeutic performance, reducing viability by 50-70% in MCF-7, U-87 MG, and PANC-1 cancer cells at 1-10 μM while maintaining >95% viability in noncancerous fibroblasts. This represents a >20-fold improvement in therapeutic index compared to free diclofenac. G2-(Dicl)9-(mPEG)12 displayed potent but cell-line-dependent activity, with highest efficacy in MCF-7 cells. Both dendrimers required 10-100× lower concentrations than free diclofenac to induce comparable reactive oxygen species (ROS) levels, with G1 producing 3-4-fold ROS elevation at 10 μM and G2 achieving similar induction at 0.1 μM. Mechanistic analysis confirmed ROS-mediated cytotoxicity as a key contributing pathway and correlated directly with cytotoxicity across various cancer models. These findings establish HFDs as an adaptable nanomedicine platform for repurposing clinically approved drugs, with G1 dendrimer providing the optimal balance of efficacy, selectivity, and translational potential.
More Related Videos
11:27Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
Published on: December 4, 2016
14:46Dendrimer-based Uneven Nanopatterns to Locally Control Surface Adhesiveness: A Method to Direct Chondrogenic Differentiation
Published on: January 20, 2018
Related Concept Videos
ATP Driven Pumps I: An Overview
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
Xylem and Transpiration-driven Transport of Resources
ATP Driven Pumps II: P-type Pumps
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
ATP Driven Pumps III: V-type Pumps
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
Secondary Active Transport
Primary Active Transport